Our lead program is a best-in-class agent developed using a proprietary chemistry platform to enable the synthesis of previously impossible structures with differentiated antimicrobial activity. Currently in late preclinical stage, this broad spectrum agent is designed to address a range of infection types including cUTI, HABP/VABP, and neonatal sepsis/BSI.¹

Our second program is a novel agent designed to reduce the burden of care in the treatment of chronic pulmonary infections.

Our third program is focused on developing a treatment with a novel mechanism of action for combating challenging Gram-negative infections.²

Through a prior acquisition, we have an additional pipeline of Gram-negative antibacterials, currently parked while we focus on our primary target profiles, and which we estimate ~12-18 months to candidate if activated. This gives us flexibility to respond to changes in the external environment—for example, passage of incentive legislation, macroeconomic reimbursement changes, or evolving antibiotic resistance patterns—by rapidly elevating the programs that best fit the commercial opportunity and address unmet patient needs.

1. This project has been funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. 75N93020C00018

2. This project has been funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. 75N93022C00061